UK Medical Cannabis Market Reaches £100M Annual Revenue

The UK's legal medical cannabis market has reached a significant milestone, crossing the £100 million annual revenue mark for the first time. Industry analysts attribute the growth to a combination of rising patient registrations, expanding prescriber networks, and increased product availability from both domestic and international suppliers.

A Market Coming of Age

When medical cannabis was rescheduled under the Misuse of Drugs Regulations in November 2018, the UK market was nascent and largely inaccessible to ordinary patients. Just a handful of specialist clinics operated in the country, and products were limited in variety and frequently expensive.

That picture has changed dramatically. The £100 million figure represents combined revenue from clinic consultations, prescription fees, and product sales dispensed through licensed pharmacies. Industry observers suggest the market could grow to £500 million or beyond by the end of the decade if patient numbers continue on their current trajectory.

Key Growth Drivers

• Patient numbers now exceeding 150,000 active prescriptions
• More than 200 pharmacies now stocking licensed cannabis medicines
• New entrants from the Netherlands, Germany, and Canada increasing supply diversity
• Growing awareness among GPs and specialist physicians
• Falling product prices making ongoing treatment more affordable

What This Means for Patients

A maturing market benefits patients directly. Increased competition among suppliers has driven product prices down significantly from the early years of legalisation, and a wider formulary means patients can work with their prescribers to find the product best suited to their individual needs.

The growth of the pharmacy dispensing network has also improved convenience considerably. Patients in most parts of the UK can now access their prescriptions through a local pharmacy rather than relying solely on mail-order dispensing services.

Looking Ahead

Despite the positive trajectory, patient advocates continue to call for NHS reimbursement of cannabis-based medicinal products. While a small number of NHS prescriptions are issued annually — primarily for paediatric epilepsy — the vast majority of patients fund treatment privately. Progress on reimbursement could unlock significantly faster market growth and broaden access to patients who currently cannot afford private treatment costs.

For the latest pricing data across the UK market, visit our price comparison tool.